Aspire Biopharma Holdings (ASBP) Total Non-Current Liabilities (2022 - 2025)

Aspire Biopharma Holdings (ASBP) has reported Total Non-Current Liabilities for 4 consecutive years, with $7.6 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Total Non-Current Liabilities rose 543.26% year-over-year to $7.6 million in Q4 2025; TTM through Dec 2025 was $7.6 million, a 543.26% increase from a year earlier, with the FY2025 full-year figure at $7.6 million, up 543.26% from the prior year.
• Total Non-Current Liabilities was $7.6 million for Q4 2025 at Aspire Biopharma Holdings, down from $8.6 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $11.1 million in Q4 2022 and troughed at $247480.0 in Q4 2023.
• A 4-year average of $4.5 million and a median of $4.0 million in 2024 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities slumped 97.77% in 2023 and jumped 543.26% in 2025, its largest moves.
• Over 4 years, Total Non-Current Liabilities stood at $11.1 million in 2022, then plunged by 97.77% to $247480.0 in 2023, then surged by 380.39% to $1.2 million in 2024, then jumped by 543.26% to $7.6 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $7.6 million (Q4 2025), $8.6 million (Q2 2025), and $8.0 million (Q1 2025), per Business Quant data.